Prenatal Paracetamol Linked to Ovarian Changes
A study found associations between prenatal exposure and altered reproductive development in female infants.
Updated on Sept. 20, 2026 in Pregnancy
Live Poll
Is now a good time to reconsider using over-the-counter pain medication during pregnancy?
A study of 302 infant girls suggests that prenatal exposure to paracetamol may be linked to smaller ovaries, fewer ovarian follicles, and reduced uterine size. With up to 65% of women in the United States using the medication during pregnancy, these findings prompt further investigation.
Why it matters
Understanding the potential developmental impacts of common medications during pregnancy is critical for informing prenatal care. This research follows recent regulatory scrutiny regarding the use of acetaminophen by pregnant individuals.
In a cohort study of 302 infant girls, researchers identified associations between maternal paracetamol use and smaller ovarian and uterine measurements at three months of age. While experimental animal studies have indicated similar links, this human data is preliminary.
The players
FDA
The federal agency responsible for regulating pharmaceuticals and communicating safety information to healthcare providers.
Janssen
A pharmaceutical company that researches and develops a wide range of medications.
The details
Researchers utilized bi-weekly usage reports and urine samples during pregnancy to track paracetamol exposure levels. By the time infants reached three months of age, the study team conducted physical examinations to measure ovarian and uterine development. The results build on previous observations in animal models which suggested potential disruptions to ovarian follicles and egg counts following prenatal exposure.
Timeline
2018: A Janssen epidemiologist noted evidence of potential connections.
September 2025: DCNF reported on Janssen internal acknowledgments.
September 22, 2025: The FDA issued a notice to physicians regarding acetaminophen use.
September 20, 2026: The study on reproductive organ development was published.
Health Landscape
This study marks a significant addition to the ongoing investigation into the long-term safety of common prenatal medications. It directly follows the regulatory warnings issued by the FDA in September 2025 regarding the use of acetaminophen during pregnancy.
If you are pregnant or planning to be, it is important to discuss all medication use, including over-the-counter pain relievers, with your obstetrician. These findings reinforce the importance of evaluating the necessity of any drug exposure during pregnancy with a qualified clinician.
The takeaway
Current research suggests a potential link between prenatal paracetamol exposure and early reproductive organ development in female infants. As this remains an area of active investigation, always consult your physician before changing or starting any medication regimen during pregnancy.
What happens next
Researchers intend to perform larger-scale studies with extended follow-up periods to determine the long-term clinical relevance of these findings.
Further reading
For more on monitoring fetal health and safety, visit Pregnancy.
Live Poll
Is now a good time to reconsider using over-the-counter pain medication during pregnancy?
